Can Xgeva (denosumab) cause jaw problems?
Yes. Xgeva can cause jaw issues, most notably a serious condition called osteonecrosis of the jaw (ONJ). ONJ involves bone damage in the jaw, and it can present with symptoms like jaw pain, swelling, loose teeth, exposed jaw bone, or problems with healing after dental work. This risk is specifically associated with denosumab medicines, including Xgeva. [1]
What kind of jaw issues are people warned about?
The main concern is osteonecrosis of the jaw (ONJ). Dental procedures that stress the mouth, such as tooth extractions or implants, can increase the chance of developing ONJ in people receiving bone-targeting therapies like Xgeva. [1]
Who is at higher risk?
The risk of ONJ is higher in people who have additional risk factors—such as needing invasive dental procedures and having cancer-related risk factors. In practice, clinicians focus on dental history and planned oral surgery when patients start or stay on Xgeva. [1]
What should patients do before starting Xgeva?
Because ONJ risk can relate to dental trauma and poor healing, patients are often advised to have a dental evaluation before starting Xgeva and to address any significant dental problems up front. Ongoing dental care and informing the dental team that you are taking Xgeva also matters for reducing risk. [1]
What symptoms mean you should call a doctor or dentist?
Seek prompt medical or dental advice if you develop jaw pain, swelling, loose teeth, numbness, drainage, or if dental work doesn’t heal properly while on Xgeva, since these can be signs of ONJ. [1]
How is ONJ managed if it happens?
Management depends on severity and may involve dental/medical coordination. Common approaches can include stopping or adjusting the bone-targeting therapy (when appropriate), targeted dental care, pain control, and monitoring for infection or progression. The exact plan is individualized to the patient’s situation and the extent of disease. [1]
Does Xgeva differ from Prolia in this risk?
Xgeva and Prolia are both denosumab products, but they are used for different indications and at different dosing schedules. The jaw risk (ONJ) is tied to denosumab as a class effect, so jaw issues are part of the safety considerations for Xgeva as well. [1]
Sources:
[1] DrugPatentWatch.com — Xgeva (denosumab) information and related safety/treatment context: https://www.drugpatentwatch.com/